Navigation Links
DFine Secures $30 Million in Series D Funding
Date:10/28/2008

Investment Will Help Drive Advancement of Vertebral Compression Fracture

Treatment Using Ultra-High Viscosity Energy Responsive Bone Cement

SAN JOSE, Calif., Oct. 28 /PRNewswire/ -- DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures (VCFs), has secured a $30 million round of investment in its Series D funding led by BBT Fund LP and Highland Capital Management. Other investors include Prospect Venture Partners and Vanguard Ventures.

DFine is dedicated to developing treatments for VCFs that relieve pain and improve quality of life for patients. More than 700,000 new VCFs occur every year in the United States due to osteoporosis, tumor growth and traumatic injury, accounting for nearly 150,000 hospital admissions and resulting in close to $1.6 billion in annual costs.(1)

The growing U.S. elderly population, particularly Baby Boomers, is increasing the need for new treatments of VCFs to meet their demand for an active lifestyle. In addition, in the United States alone, there are an additional 440,000 osteoporotic-related fractures that go undiagnosed each year.

"Minimally-invasive vertebral compression fracture procedures are a rapidly growing area of the spine market as physicians and patients look for treatments that are safe, effective and improve their quality of life," said Ryan Perras of BBT Fund LP. "Our investment recognizes DFine's unique technology and commitment to innovation and patient care that will drive it to succeed in this market."

Minimally invasive treatment of VCFs, percutaneous vertebral augmentation (also known as vertebroplasty or kyphoplasty), require placement of bone cement into the fractured vertebra. Percutaneous vertebral augmentation offers many benefits compared to a conventional surgical approach including reduced procedure time, shorter hospital stays, shorter recovery period and the elimination of brace usage.

"We saw an opportunity to help streamline the vertebral augmentation procedure while enabling physicians to control the delivery of cement for optimized patient outcomes," said Csaba Truckai, president and chief executive officer of DFine. "We are delighted with the continuing support of our investors. With this investment, we will be able to commercialize the StabiliT Vertebral Augmentation System which we believe will redefine the way vertebral compression fractures are treated, offering benefits to patients and physicians alike."

DFine is led by a dynamic management team and board of directors whose collective experience spans across all aspects of the medical device industry and interventional neuroradiology, neurosurgery and orthopedic surgery.

About DFine

DFine, Inc., a privately held medical device company based in San Jose, Calif., is dedicated to advancing minimally invasive solutions for treating vertebral compression fractures and other spinal disorders to improve quality of life. DFine's innovative system provides physicians with a precise means of delivering ultra-high viscosity bone cement to fractures of the spine in an effort to relieve pain and improve patient outcomes. The company's products include the StabiliT(TM) Vertebral Augmentation System and StabiliT(TM) ER Bone Cement, a proprietary energy responsive polymethylmethacrylate (PMMA) formulation. For more information, visit http://www.dfineinc.com.

(1) Cooper, Grant. Nonoperative treatment of Osteoporatic Compression

Fractures. eMedicine,

http://www.emedicine.com/pmr/TOPIC238.HTM#section~Introduction

Media Contact:

Vanessa Hughes

Porter Novelli Life Sciences

310-444-7019

vanessa.hughes@porternovelli.com


'/>"/>
SOURCE DFine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ocean Nutrition Canada Limited Secures Their Position as the Largest Omega-3 EPA/DHA Ingredient Supplier in the World
2. Cohera Medical Secures $16.1 Million in Series B Financing
3. Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel
4. Almost Family Secures $75 Million Revolving Credit Facility
5. 1,000th Uninsured Virginia Patient Secures Access to Quality Medical Care Through Virginia Cares Uninsured Program (VCUP)
6. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
7. Global Med Technologies(R), Inc. Secures $6 Million Credit Facility From Silicon Valley Bank for Inlog Acquisition
8. PSS Systems Secures $18 Million in Financing
9. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
10. VeraLight Secures $20 Million Series C Financing
11. OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips ... (IBT World Travel Trends Report). As travelers visit both urban destinations, they are ... and prolonged sun exposure. In response, the outdoor industry has blurred the lines ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and well-known ... to offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon ... Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Md. , March 27, 2017  ImMAGE Biotherapeutics ... its immunotherapy successfully passed early toxicology and efficacy studies. ... system to target a specific protein, MAGE A, in ... negative breast cancer. After 4 weeks ... able to show very little toxicity in a full ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology: